Clinical trials: Cutaneous Leishmaniasis
Leishmaniasis, Cutaneous
A Study of a New Leishmania Vaccine Candidate ChAd63-KH
This is a study to assess the safety of a new candidate Leishmania vaccine ChAd63-KH in patients with persistent post kala azar dermal leishmaniasis (PKDL).
- Trial name
- Leish2a (NCT02894008)
- Testing
- ChAd63-KH
- Where
- Sudan
- Volunteers
- 24 people
- Sponsor
- University of York
Cutaneous Leishmaniasis (Diagnosis)
Performance of RPA-LF for Cutaneous Leishmaniasis
CL is public health in the Americas, diagnostic confirmation is required to start treatment, however current diagnostic methods have several limitations and its access is limited.
- Trial name
- RPA-LF (NCT04500873)
- Where
- Colombia
- Volunteers
- 128 people
- Sponsor
- Centro Internacional de Entrenamiento e Investigaciones Médicas
Cutaneous Leihmaniasis
Short Course of Miltefosine and Antimony to Treat Cutaneous Leishmaniasis in Bolivia
The combination of a half-course of miltefosine and a half-course of antimony will be evaluated for efficacy and tolerance. The combination of miltefosine and antimony is chosen because these are now the two standard agents in…
- Trial name
- NCT00537953
- Testing
- Miltefosine , meglumine antimoniate
- Where
- Bolivia
- Sponsor
- Centro de Investigaciones Bioclínicas de la Fundación Fader
Leishmaniasis, Cutaneous
Arnica Tincture Fot the Treatment of Cutaneous Leishmaniasis
Cutaneous Leishmaniasis (CL) is a parasitic disease caused by more than 20 different species of the protozoan parasite Leishmania.
- Trial name
- ARNICA (NCT05094908)
- Testing
- Arnica Tincture
- Where
- Colombia
- Volunteers
- 16 people
- Sponsor
- Universidad de Antioquia
Kinetoplastid, Skin Diseases, Parasitic
Diagnosis and Treatment of Leishmania Infections
Patients admitted on this protocol must have an active Leishmania infection. The major objectives of the protocol are to diagnose and classify the Leishmania infection and to provide species-based therapy to study the natural…
- Conditions
- Kinetoplastid, Skin Diseases, Parasitic, Parasitic Diseases, Leishmaniasis
- Trial name
- NCT00344188
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Leishmaniasis
The Association of Miltefosine and Pentoxifylline to Treat Mucosal and Cutaneous Leishmaniasis: A Clinical Trial in Brazil
Mucocutaneous leishmaniasis is endemic in the central region of Brazil and other countries worldwide. The standard treatment with meglumine antimoniate has a high rate of important adverse effects.
- Trial name
- NCT02530697
- Testing
- Meglumine antimoniate, Miltefosine, Pentoxifylline
- Where
- Brazil
- Volunteers
- 160 people
- Sponsor
- University of Brasilia
Localized Cutaneous Leishmaniasis
Low-dose Pentavalent Antimony Treatment of Cutaneous Leishmaniasis in Old Age Patients
This study was designed to evaluate the effect of low doses of pentavalent antimony (meglumine antimoniate) to treat cutaneous leishmaniasis ulcers in patients older than 65 years.
- Trial name
- Sbold (NCT00818818)
- Testing
- Meglumine antimoniate
- Where
- Brazil
- Volunteers
- 13 people
- Sponsor
- University of Brasilia
Leishmaniasis, Mucocutaneous
Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Mucosal Leishmaniasis
The purpose of this study is to evaluate the safety of the Leish-111f + MPL-SE vaccine given as three injections every 28 days at each of three dose levels of Leish-111f protein, in combination with standard pentavalent antimony…
- Trial name
- NCT00111514
- Testing
- Leish-111f + MPL-SE vaccine
- Where
- 2 sites in Peru
- Volunteers
- 48 people
- Sponsor
- Access to Advanced Health Institute (AAHI)
Cutaneous Leihmaniasis
Study Comparing Several Drugs to Understand Which Work Against Cutaneous Leishmaniasis (CL)
MAMS4CL comprises a clinical trial with three embedded sub-studies designed to comprehensively evaluate the administered treatments and assess the impact of CL treatment on patients and the healthcare system.
- Trial name
- NCT07463040
- Testing
- Sodium Stibogluconate (SSG), Miltefosine, Miltefosine + Paromomycin
- Where
- 3 sites in Ethiopia
- Volunteers
- 900 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Cutaneous Leishmaniasis
Intralesional Injection of Metronidazole for the Management of Cutaneous Leishmaniasis
Aim of the study to evaluate the effectiveness of intralesional metronidazole 0.5% solution as a local injection in treating cutaneous leishmaniasis.
- Trial name
- NCT06798415
- Testing
- Metronidazole
- Where
- Iraq
- Volunteers
- 40 people
- Sponsor
- Hayder Adnan Fawzi
Cutaneous Leishmaniases
Diagnosis of Cutaneous Leishmaniasis Using the CL-detect Rapid Test in Travelers and Migrants in Belgium
Cutaneous Leishmaniasis (CL) is a neglected tropical disease which is increasingly seen in travelers and migrants evaluated in travel clinics of non-endemic countries.
- Trial name
- RapidLeish (NCT04001335)
- Testing
- Dental Broach
- Where
- Belgium
- Volunteers
- 6 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Cutaneous Leishmaniasis, American
Tofacitinib Associated With Meglumine Antimoniate in Cutaneous Leishmaniasis
Phase 2/3 randomized and controlled clinical trial, which will evaluate the effectiveness of the association meglumine antimoniate (Glucantime) with tofacitinib in the cure of CL and the capacity of this association to reduce the…
- Trial name
- CLTofa23 (NCT06011343)
- Testing
- Oral tofacitinib, Parenteral meglumine antimoniate
- Where
- Brazil
- Volunteers
- 22 people
- Sponsor
- Hospital Universitário Professor Edgard Santos
Cutaneous Leishmaniases
Effectiveness, Safety and Feasibility of HECT-CL, in Quetta, Pakistan
This research studies the effect thermotherapy as treatment of Old World CL which is not invasive, non-toxic, and the short treatment. While the current standard treatment comprise daily painful injections with antimonials,
- Trial name
- HECT-CL (NCT03208543)
- Testing
- HECT-CL
- Where
- Pakistan
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Medecins Sans Frontieres, Netherlands
PKDL
Safety and Efficacy of Oral Miltefosine in Patients With Post Kala Azar Dermal Leishmaniasis (PKDL)
Miltefosine efficacy will be >85%
- Trial name
- NCT01635777
- Testing
- Miltefosine
- Where
- India
- Volunteers
- 37 people
- Sponsor
- AB Foundation
Leishmaniasis; Brazilian, Leishmaniasis, Mucocutaneous
Pilot Study: Oral Treatment of American Tegumentary Leishmaniasis (Cutaneous and Mucosal Forms) in the Elderly
Randomised clinical trial comparing oral miltefosine associated with pentoxifylline to intravenous liposomal amphotericin b for the treatment of cutaneous and mucosal leishmaniasis
- Trial name
- NCT06040489
- Testing
- Miltefosine 50mg, Pentoxifylline 400mg, Liposomal Amphotericin B
- Where
- Brazil
- Volunteers
- 100 people
- Sponsor
- University of Brasilia
Cutaneous Leishmaniasis
Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama
This study is a pivotal Phase 3, randomized, double-blind, 3-site, two-group trial assessing the efficacy and safety of WR 279,396 Topical Cream and Paromomycin Alone Topical Cream in subjects with CL in Panama.
- Trial name
- NCT01790659
- Testing
- WR 279,396, Paromomycin
- Where
- Panama
- Volunteers
- 399 people
- Sponsor
- U.S. Army Medical Research and Development Command